Kim Champion

Caractéristiques de la prise en charge des patients avec une artérite à cellules géantes diagnostiquée récemment, étude NEWTON

G. Peyrac, N. Lomba Goncalves, A. Kante, P. Cacoub et autres

fr (code pays fourni par la source)

Traitement par tocilizumab en vie réelle au cours de l’artérite à cellules géantes, étude Toci-NEWTON

G. Peyrac, N. Lomba Goncalves, A. Kante, P. Cacoub et autres

fr (code pays fourni par la source)

Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial

Karl S. Peggs, Sarah J. Albon, Macarena Oporto Espuelas, Catherine Irving et autres

BACKGROUND AIMS: Delayed immune reconstitution is a major challenge after matched unrelated donor (MUD) stem cell transplant (SCT). In this randomized phase 2 multi-center trial, Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant …

gb (code pays fourni par la source)

Novel biomarker-driven trial of a cell and gene therapy for the treatment of malignant pleural mesothelioma (MPM): the STRATEGIC trial

Alun M. Davies, Beth Sage, Krishna K. Kolluri, R. L. Graham et autres

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Claire Roddie, Maeve O’Reilly, Maria A. V. Marzolini, Leigh Wood et autres

Introduction: 2nd generation CD19 CAR T cells show unprecedented efficacy in B-ALL, but several challenges remain: (1) scaling manufacture to meet patient need and (2) feasibility of generating products from lymphopenic patients post allogeneic stem cell transplant (allo-SCT). To overcome these issues …

gb (code pays fourni par la source)

Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans

Christine Rivat, Natalia Izotova, Rachael T. Richardson, Danilo Pellin et autres

CD19 CAR-T cells show unprecedented responses in relapsed/refractory Acute Lymphoblastic Leukaemia, but long-term persistence appears critical for their use as a stand-alone therapy. The origin of long-term persisting CAR-T cells has yet to be defined and will be critical in designing manufacturing …

gb, us (code pays fourni par la source)

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Karl S. Peggs, Sarah J. Albon, Catherine Irving, Rachel Richardson et autres

Karl S Peggs and Sarah J Albon contributed equally to the work and are joint first author Introduction Alemtuzumab reduces the incidence of GVHD after unrelated donor stem cell transplant (MUD SCT) but delays immune reconstitution resulting in high morbidity/mortality from viral …

gb (code pays fourni par la source)

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Claire Roddie, Maeve O’Reilly, Maria A. V. Marzolini, Leigh Wood et autres

Introduction: In adults, prognosis for B-ALL is poor, patients are more vulnerable to CD19 CAR immunotoxicity and there is currently no CD19 CAR therapeutic with acceptable toxicity and durable efficacy. We have developed a novel second generation CD19CAR (CAT-41BBz CAR), with a …

gb (code pays fourni par la source)

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Sara Ghorashian, Anne Marijn Kramer, Shimobi Onuoha, Gary Wright et autres

Introduction: The CARPALL study (NCT02443831) employed a novel CD19CAR (CAT-41BBz CAR) with a faster off rate than the Kymriah FMC63-41BBz CAR (CAT 3.1x10-3s-1, FMC 6.8 x 10-5s-1), with equivalent on-rate (CAT 2.2 x 105, FMC 2.1 x 105). We herein report updated …

gb (code pays fourni par la source)

P2.01-16 TACTICAL: A Phase I/II Trial to Assess the Safety and Efficacy of MSCTRAIL in Metastatic Lung Adenocarcinoma

Annabelle Davies, Elizabeth K. Sage, Krishna K. Kolluri, Rosalind Graham et autres

gb (code pays fourni par la source)

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Sara Ghorashian, Anne Marijn Kramer, Shimobi Onuoha, Gary Wright et autres

gb (code pays fourni par la source)

Abstract CT105: AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL

Claire Roddie, Maeve O’Reilly, Juliana Dias, Ketki Vispute et autres

Introduction: CD19 CAR T therapy has advanced treatment of relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (B-ALL). However, several challenges remain including: (1) considerable toxicity of CD19 CAR therapy; (2) the need for long-term persistence to deliver sustained response; (3) requirement for robust, cost …

gb (code pays fourni par la source)